Management Team

Mr. Greenleaf has served as President, Chief Executive Officer and Director since 2019. From 2018 through its acquisition by Collegium Pharmaceutical, Inc. in 2022, he served as Chairman of BioDelivery Sciences International, Inc. From 2018 through its acquisition by Halozyme Therapeutics, Inc. in 2022, Mr. Greenleaf served as Director of Antares Pharma, Inc. From 2018 to 2019, he served as Chief Executive Officer and Director of Cerecor Inc. From 2014 through its acquisition by Mallinckrodt plc in 2018, Mr. Greenleaf served as Chief Executive Officer and Chairman of Sucampo Pharmaceuticals, Inc. From 2013 to 2014, he served as Chief Executive Officer and Director of Histogenics Corporation (now Ocugen, Inc.). From 2006 to 2013, Mr. Greenleaf held various positions at MedImmune, Inc. (now AstraZeneca PLC), most recently serving as President. From 2010 to 2013, he served as President of MedImmune Ventures, Inc. (now AstraZeneca PLC). From 1998 to 2006, Mr. Greenleaf held various positions at Centocor, Inc. (now Johnson & Johnson), most recently serving as Senior Vice President of the Remicade Franchise. From 1996 to 1998, he held various positions at Boehringer Mannheim G.m.b.H. (now Roche Holding Ltd.), most recently serving as District Manager. Mr. Greenleaf received a B.S. degree from Western Connecticut State University and an M.B.A. degree from St. Joseph’s University.

‍

‍

Mr. Donley has served as Chief Operating Officer since 2024 and previously as the Executive Vice President, Operations and Strategy from 2019 to 2024. From 2018 to 2019, he served as Global Head, Human Resources, Information Technology and Facilities at Senseonics Holdings, Inc. From 2014 through its acquisition by Mallinckrodt plc in 2018, Mr. Donley served as Executive Vice President of Global Human Resources, Information Technology and Corporate Strategy at Sucampo Pharmaceuticals, Inc. From 2000 to 2013, he served as Executive Vice President, Human Resources and Corporate Affairs at MedImmune, Inc. (now AstraZeneca PLC). Mr. Donley received a B.A. degree from the University of Michigan and an M.B.A. degree from George Mason University.

‍

Mr. Miller has served as Chief Financial Officer since 2020. From 2018 to 2020, he held various positions at Cerecor Inc., most recently serving as Chief Financial Officer, Principal Executive Officer and Corporate Secretary. From 2015 through its acquisition by Mallinckrodt plc in 2018, Mr. Miller served as Vice President of Finance at Sucampo Pharmaceuticals, Inc. From 2006 to 2015, he held various positions at QIAGEN N.V., most recently serving as Senior Director of Accounting. From 2002 to 2006, Mr. Miller held various positions at Eppendorf, Inc., most recently serving as Vice President of Finance and Chief Financial Officer. From 1998 to 2002, he held various positions in the assurance practice at KPMG LLP. Mr. Miller received a B.S. degree from Villanova University and is a Certified Public Accountant.

Mr. Robertson has served as Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer since 2020. From 2014 to 2020, he served as Partner at Borden Ladner Gervais LLP. From 2015 to 2020, Mr. Robertson served as an Adjunct Professor at the Allard School of Law at the University of British Columbia. Mr. Robertson received an LL.B. degree from the University of Manitoba.

‍

Dr. Keenan has served as Senior Vice President, Chief Medical Officer since 2023. From 2021 to 2023, he held various positions at ValenzaBio, Inc. (now Alumis Inc.), most recently serving as Chief Medical Officer. From 2020 to 2021, Dr. Keenan served as Senior Vice President, Global Head of Medical and Drug Safety at AVROBIO, Inc. (now Tectonic Therapeutic, Inc.). From 2013 to 2018, he served as Vice President, U.S. Medical Affairs and Head Medical Officer at AstraZeneca PLC. From 2010 to 2012, Dr. Keenan served as Vice President at Human Genome Sciences, Inc. (now GSK plc). From 1999 to 2010, he held various positions at Centocor, Inc. (now Johnson & Johnson), most recently serving as Leader, Medical Affairs and Strategic Trials Team. Dr. Keenan received a B.A. degree from Colby College and an M.D. degree from Albany Medical College and completed a Pediatric and Adult Rheumatology Fellowship at the University of Pennsylvania.

‍

Dr. Ramiya has served as Senior Vice President, Manufacturing and Supply Chain since 2022. From 2018 to 2022, he served as Vice President of Chemistry, Manufacturing and Controls and Bio Analytical Operations at Cerus Corporation. From 2016 to 2018, Dr. Ramiya served as Executive Director, API Synthesis and Formulation Development at Intarcia Therapeutics, Inc. (now i2o Therapeutics, Inc.). From 2015 to 2016, he served as Vice President, Pharmaceutical Development and Supply Chain at Carbylan Therapeutics, Inc. (now KalVista Pharmaceuticals, Inc.). From 2004 to 2015, Dr. Ramiya held various positions at Geron Corporation, most recently serving as Vice President, Process Development and Manufacturing. From 2001 to 2004, he served as Senior Director of Process Research and Development at deCODE genetics, Inc. (now Amgen Inc.). From 1993 to 2001, Dr. Ramiya served as Senior Scientist/Team Lead at Abbott Laboratories. Dr. Ramiya received B.S. and M.S. degrees from Madurai Kamaraj University and a Ph.D. from the Indian Institute of Science.

‍

Mr. Ahern has served as Vice President, Regulatory Affairs since 2025. From 2023 to 2024, he served as Managing Partner at Revelstone Consulting. From 2017 to 2022, Mr. Ahern served as Vice President, Global Regulatory Affairs at Jazz Pharmaceuticals. From 2008 to 2017, he held various positions at Teva Pharmaceutical Industries Ltd., most recently serving as Global Therapeutic Area Regulatory Head. From 2004 to 2008, Mr. Ahern served as Associate Director at Shire PLC (now Takeda Pharmaceutical Co., Ltd.). From 2002 to 2004, he served as Associate Director of Regulatory Affairs at AstraZeneca PLC. From 1996 to 1998, Mr. Ahern served as a Regulatory Coordinator at Wyeth (now Pfizer Inc.). Mr. Ahern received a B.S. degree from Pennsylvania State University and an M.S. degree from Temple University.

Ms. Dardeno has served as Vice President, Global Patient Safety since 2021. From 2018 to 2021, she served as Vice President, Pharmacovigilance and Risk Management at Clementia Pharmaceuticals Inc. (now Ipsen S.A.). From 2017 to 2018, Ms. Dardeno served as Vice President, Head of Pharmacovigilance and Risk Management at Aegerion Pharmaceuticals, Inc. (now Chiesi Farmaceutici S.p.A.). From 2014 to 2017, she served as Head of Pharmacovigilance and Risk Management at Merrimack Pharmaceuticals, Inc. (now Ipsen S.A.). From 2012 to 2014, Ms. Dardeno served as Head of Drug Safety and Pharmacovigilance at Tesaro, Inc. (now GSK plc). From 2011 to 2012, she served as Head of Clinical Safety and Pharmacovigilance at Enobia Pharma Corporation (now AstraZeneca PLC). From 1998 to 2011, Ms. Dardeno held various positions at Genzyme Corporation (now Sanofi), most recently serving as Director of Global Patient Safety and Risk Management. Ms. Dardeno received a B.S. degree from the Massachusetts College of Pharmacy and Health Sciences.

Mr. Gammons has served as Vice President, Chief Information Officer since 2021. From 2018 to 2021, he served as Chief Information Officer and Vice President of Information Technology at Autolus Therapeutics plc. From 2015 through its acquisition by Mallinckrodt plc in 2018, Mr. Gammons served as Chief Information Officer, Vice President Information Technology at Sucampo Pharmaceuticals, Inc. From 2004 to 2015, he held various positions at AstraZeneca PLC, most recently serving as Director, Information Systems Business Management and Business Analysis. Mr. Gammons received a B.S. degree from West Virginia University and an M.B.A. degree from Hood College.

Mr. Harrell has served as Vice President, Marketing since 2023. From 2018 to 2022, he held various positions at Cerecor Inc., most recently serving as Chief Commercial Officer. From 2013 to 2018, Mr. Harrell served as Principal and Executive Vice President at NSCI Group, Inc. (now US HealthConnect, Inc.). From 2011 to 2013, he served as the General Manager of the U.S. Pain Franchise at Covidien plc (now Medtronic plc). From 2007 to 2010, Mr. Harrell served as Vice President of Marketing for the Pediatric Infectious Disease Group at MedImmune, Inc. (now AstraZeneca PLC). Mr. Harrell received a B.S. degree from Samford University.

Ms. Kennedy has served as Vice President, Financial Planning and Analysis since 2017. From 2014 to 2015, she served as Associate Director, Commercial Finance at Shire PLC (now Takeda Pharmaceutical Co. Ltd.). From 2006 through its acquisition by Shire PLC (now Takeda Pharmaceutical Co. Ltd.) in 2014, Ms. Kennedy held various positions at ViroPharma Inc., most recently serving as Manager, Financial Information Systems. From 2004 to 2006, she served as an internal auditor at PricewaterhouseCoopers LLP. Ms. Kennedy received a B.S. degree from Pennsylvania State University.

Mr. Lewis has served as Vice President, Sales since 2023. From 2022 to 2023, he served as Vice President, Sales Opthamology at Horizon Therapeutics plc (now Amgen Inc.). From 2010 to 2022, Mr. Lewis served as Vice President, Sales Specialty at GSK plc. From 1998 to 2010, Mr. Lewis held various positions with Centocor, Inc. (now Johnson & Johnson), most recently serving as National Director of Sales Immunology. Mr. Lewis received a B.B.A. degree from Valdosta State University.

Ms. Matthews has served as Vice President, Organizational Development since 2022. From 2019 to 2022, she served as Senior Vice President, Development Consultant at Citizens Financial Group, Inc. From 2013 to 2019, Ms. Matthews served as Director, Global Human Resource Business Partner at AstraZeneca PLC. From 2008 to 2013, she served as Director, Talent Management and Partner at MedImmune, Inc. (now AstraZeneca PLC). Ms. Matthews received an M.S.c. degree from New School for Social Research.

Ms. Meister has served as Vice President, Finance since 2020. From 2014 to 2020, she served as Vice President of Internal Audit at US Silica Holdings, Inc. From 2005 to 2014, Ms. Meister served as Associate Director Internal Audit, Americas at QIAGEN N.V. From 2004 to 2005, she served as Functional Analyst at Accenture plc. Ms. Meister received a B.S. degree from the University of Maryland.

Mr. Prystawa has served as Vice President, Quality Assurance since 2017. From 2016 to 2017, he served as Director of Quality Assurance and Regulatory Affairs at Translational Research (now The Halifax Group LLC and SV Life Sciences). From 2014 to 2016, Mr. Prystawa served as an Independent GxP Consultant at TEC Edmonton. From 2012 to 2014, he served as the Quality Assurance Manager at Edmonton Radiopharmaceutical Center. From 2006 to 2012, Mr. Prystawa served as Quality Manager at Isotechnika Pharma Inc. (now Aurinia Pharmaceuticals Inc.). From 2000 to 2006, he served as a Quality Assurance/Quality Control Specialist at Alberta Research Council (now Alberta Innovates). From 1997 to 2000, Mr. Prystawa served as a Quality Control Specialist at Raylo Chemicals Inc. (now Gilead Sciences, Inc.). Mr. Prystawa received a B.S. degree from the University of Alberta.

Ms. Rogers has served as Vice President, Commercial Supply Chain and Patient Services since 2020. From 2018 to 2020, she served as Vice President, Global Distribution, Patient Access and Support Services at Orchard Therapeutics PLC (now Kyowa Kirin Co., Ltd.). From 2017 through its acquisition by Mallinckrodt plc in 2018, Ms. Rogers served as Vice President, Global Patients Services and Channel Management at Sucampo Pharmaceuticals, Inc. From 2006 to 2017, she served as Executive Director, Patient Services, Distribution and Trade Relations at Alexion Pharmaceuticals, Inc. (now AstraZeneca PLC). From 2002 to 2006, Ms. Rogers served as Head of Trade Relations, U.S. Supply Chain and Customer Operations at Bayer Corporation. Ms. Rogers received a B.S. degree from Salve Regina University.

Ms. Shieh has served as Vice President, Human Resources, Operations since 2020. From 2019 to 2020, she served as Associate Director, Human Resources at Autolus Therapeutics plc. From 2015 to 2019, Ms. Shieh served as Human Resources Director at North Highland Worldwide Consulting. From 2014 to 2015, she served as Senior Human Resources Generalist at Tasly Pharmaceuticals, Inc. From 2011 to 2014, Ms. Shieh served as Human Resources Business Partner III at Automatic Data Processing, Inc. From 2004 to 2011, she served as Senior Human Resources Generalist at Citigroup Inc. Ms. Shieh received a B.A. degree from the University of Florida.

Dr. Stone has served as Vice President, Medical Affairs since 2019. From 2016 to 2019, he served as Vice President, Medical Affairs at Alcresta Therapeutics, Inc. (now Linden Capital Partners LLC). From 2014 to 2016, Dr. Stone served as Senior Director, Medical Affairs Americas at Sirtex Medical. From 2013 to 2014, he served as Senior Director, Head of Medical Affairs at Cornerstone Therapeutics, Inc. (now Chiesi Farmaceutici S.p.A.). From 2012 to 2013, Dr. Stone served as National Director, Field Medical Affairs at Elan Corporation, plc. (now Perrigo Co. plc). From 2009 to 2012, he served as Senior Director, Head of US Medical Affairs at Merz GmbH & Co. KGaA. From 2005 to 2009, Dr. Stone served as Medical Science Liaison and Regional Medical Science Liaison Director at Allergan, Inc. (now AbbVie Inc.). From 2001 to 2005, he served as Medical Science Liaison at Sankyo Pharma, Inc. (now Daiichi-Sankyo Co., Ltd.). From 2000 to 2001, Dr. Stone served as Technical Sales Representative and Applications Specialist at Stratagene Corporation (now Agilent Technologies, Inc.). Dr. Stone received a B.S. degree from the University of Arkansas at Little Rock and a Ph.D. degree from the University of Arkansas for Medical Sciences.

Mr. Victory has served as Vice President, Corporate Development since 2020. From 2002 to 2020, he held various positions at MedImmune, Inc. (now AstraZeneca PLC), most recently serving as Vice President and Head for Cardiovascular, Renal, Metabolic and Infectious Disease, Partnering and Strategy. Mr. Victory received B.S. and B.A. degrees from Stanford University and an M.B.A. degree from Northwestern University.

Dr. Zhou has served as Vice President, Pharmacology and Pharmacometrics since 2022. From 2011 to 2022, he served as Executive Director, Clinical Pharmacology and Pharmacometrics at Celgene Corporation (now Bristol-Myers Squibb Company). From 2010 to 2011, Dr. Zhou served as Senior Director of Clinical Pharmacology Modeling and Simulation at Daiichi‑Sankyo Co., Ltd. From 2005 to 2010, he served as Director of Early Development Clinical Pharmacology at Wyeth (now Pfizer Inc.). From 2000 to 2005, Dr. Zhou served as Senior Research Investigator in Clinical Discovery at Bristol-Myers Squibb Company. From 1998 to 2000, he served as Research Scientist in Drug Discovery and Early Development at Pfizer Inc. Dr. Zhou received a B.S. degree from Sun Yat-Sen University and Ph.D. and M.S.c. degrees from the University of Michigan.